Companies / Oyster Point Pharma, Inc.
Oyster Point Pharma, Inc.
OYSTCIK 1720725
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Oct 18, 2021 | Link William J Phd Director | Sell Open-market sale | Common Stock | $4.44M | -304K -22.30% | 1,057,976 | medium |
| Oct 18, 2021 | Versant Venture Capital VI, L.P. 10% owner | Sell Open-market sale | Common Stock | $4.44M | -304K -22.30% | 1,057,976 | medium |
| Oct 18, 2021 | Ozawa Clare Director | Sell Open-market sale | Common Stock | $4.44M | -304K -22.30% | 1,057,976 | medium |
| Oct 18, 2021 | Link William J Phd Director | Sell Open-market sale | Common Stock | $3.67M | -243K -22.96% | 815,033 | medium |
| Oct 18, 2021 | Versant Venture Capital VI, L.P. 10% owner | Sell Open-market sale | Common Stock | $3.67M | -243K -22.96% | 815,033 | medium |
| Oct 18, 2021 | Ozawa Clare Director | Sell Open-market sale | Common Stock | $3.67M | -243K -22.96% | 815,033 | medium |
| Feb 24, 2021 | Lochner Daniel Executive | Exercise Option exercise | Common Stock | $104.8K | +9K +35.69% | 34,631 | low |
| Dec 1, 2022 | Nau Jeffrey CEO | Other Withheld for taxes | Common Stock | $100.1K | -9K -5.67% | 148,660 | low |